levated low-density lipoprotein cholesterol (LDL-C) is a major modifiable cause of coronary heart disease (CHD). The National Cholesterol Education Program (NCEP) periodically releases reports by its Adult Treatment Panel (ATP) providing recommendations for managing high blood cholesterol in adults. Since the 1993 ATP II guideline, 1 multiple clinical trials have demonstrated the benefits of LDL-C lowering in individuals at increased risk for CHD across a range of initial cholesterol levels. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Cholesterol lowering in adults with low short-term risk has not been well studied. The 2001 ATP guideline increased the number of individuals considered to be high risk. 16, 17 It also recommended using cholesterol-lowering medication in adults at moderately high risk of CHD with LDL-C levels above 130 mg/dL and to consider the option of using medication in low-risk adults with LDL-C levels between 160 and 189 mg/dL or high-risk adults with LDL-C levels between 100 and 129 mg/dL. Further optional modifications to the ATP III guideline, released by the NCEP in 2004, gave clinicians the choice of pursuing very low (o70 mg/dL) LDL-C levels for very high-risk adults and low (o100 mg/dL) LDL-C levels for moderately high-risk adults through using cholesterol-lowering medications and intensified lifestyle modifications (Table 1) . 18 We sought to determine the implications of these guideline changes for the U.S. population. Our primary goal was to determine the proportion of adults with LDL-C levels exceeding the ATP recommended and optional goals published 
METHODS

Study Population
The National Health and Nutrition Examination Survey (NHANES) conducted from 1999 to 2002 recruited a nationally representative sample of the noninstitutionalized U.S. population for a home interview, physical examination, and laboratory testing. The institutional review board of the National Center for Health Statistics approved the survey, and participants provided informed consent. 19 We included nonpregnant morning exam participants aged 20 to 79 years old (n =4,044). We excluded participants who had fasted fewer than 8 or more than 24 hours, (n =524), had serum triglyceride levels exceeding 400 mg/dL (n =106), did not have cholesterol measured (n =67), or for whom cor-onary risk assessment could not be performed because of missing blood pressure information (n =66).
Study Variables
We classified participants' coronary risk and LDL-C goals according to the NCEP ATP III criteria ( Table 1 ) that defined 4 risk groups. Subjects with CHD (including self-reported prior myocardial infarction or angina) were classified as high risk. Individuals with other conditions considered to carry high CHD risk-i.e., prior stroke, peripheral arterial disease (based on an ankle brachial index o0.9 or a lower extremity amputation), or diabetes (self-reported physician-diagnosed diabetes or fasting glucose 126 mg/dL)-were also classified as high risk. For individuals with 2 or more risk factors-male 45 years old, female 55 years old, a first-degree relative with CHD before age 55 years if male or 65 years if female (only data for parents and siblings with myocardial infarction or angina before age 50 years were available), cigarette smoking, hypertension ( 140/90 mm Hg or taking antihypertensive medication), or serum high-density lipoprotein cholesterol (HDL-C) o40 mg/dL-the 10-year risk of fatal CHD or nonfatal myocardial infarction was determined using a multivariable risk assessment tool derived from Framingham Heart Study. Individuals were then classified into 1 of 3 risk groups depending on their estimated 10-year risk of fatal CHD or nonfatal myocardial infarction (o10% [moderate], 10% to 20% [moderately high], or 420% [high]). Those with fewer than 2 risk factors were assigned to the lowest-risk group. The number of risk factors was reduced by 1 if the HDL-C level was 60 mg/dL. 16 
LDL-Cholesterol Levels Above Guideline Goals and Thresholds for Drug Therapy
We calculated LDL-C levels from total serum cholesterol, HDL-C, and triglyceride levels using the Friedewald equation. 20 We 21 We determined the effect of applying these guidelines on the proportion of the population exceeding NCEP guideline goals.
Data Analysis
We used SAS release 9.1 (SAS Institute Inc., Cary, NC) and SUDAAN release 9.0.1 (Research Triangle Institute, Research Triangle Park, NC) to account for the survey design and provide nationally representative proportions and accurate confidence intervals. All proportions reflect the survey weights. We used the w 2 test to compare categorical variables and the t-test for continuous variables. Significance tests were 2-sided with a P value set at o.05. We used the sampling weights (which account for the probability of selection and nonresponse) to estimate the number of noninstitutionalized nonpregnant adults aged 20 to 79 years in the U.S. population in the year 2000 in each group.
RESULTS
In total, 3,281 individuals (representing 175,600,000 U.S. adults) participated in a morning examination and had no exclusion criteria. The median age was 43.0 years and 50.7% were women (Table 2) . Age, sex, race/ethnicity, income, and cholesterol-lowering medication use did not differ significantly between excluded and included subjects. The included sample was representative of 94.1% of the nonpregnant U.S. population 20 to 79 years old. 
LDL-Cholesterol Levels Exceeding NCEP Guidelines
LDL-C Reduction Needed for Adults Not Already on Drug Therapy
Of the population not currently using cholesterol-lowering therapy, 538 (15.6% [95% CI, 13.6% to 17.7%]) exceeded their Table 4 .
DISCUSSION
We used data from 3,281 participants of the 1999 to 2002 NHANES to assess the implications of widely applying NCEP recommendations and optional thresholds. Thirty percent of the U.S. adult population had LDL-C levels exceeding ATP III goals. Furthermore, 18% of individuals not taking drug therapy exceeded their LDL-C goal by more than 10% and thus would be unlikely to reach their LDL-C target without pharmacotherapy or highly specialized diets. [21] [22] [23] [24] [25] [26] Medications to lower cholesterol were underused, especially among individuals at increased short-term risk for CHD. Our results demonstrate the impact that recent NCEP guideline changes could have on the number of individuals exceeding LDL-C goals if these recommendations were fully implemented in clinical practice. If the optional NCEP goals described in 2004 were widely adopted, 52.9 million adults (30%) not currently on medication would exceed their optional LDL-C goal, and 40 million (25%) would be more than 10% above their goal. Restricting the population screened for lipid disorders to exclude younger, low-risk individuals as described by the USPSTF guideline 27 only moderately reduced the number of U.S. adults with LDL-C levels exceeding NCEP goals. Among adults at moderately high or high cardiovascular risk, most (68%) exceed the LDL-C goal recommended by the ATP III report. Adopting the lower optional targets would mean nearly all persons in these risk groups would have LDL-C levels exceeding their goals, despite the fact that 25% of this population already used cholesterol-lowering medication.
The downward shifts in LDL-C targets raise the proportion of adults requiring intermediate (11% to 40%) and large (440%) reductions to achieve their target levels. The optional 2004 NCEP goals increased the proportion of the untreated 20-to 79-year-old population needing more than a 40% reduction in their LDL-C to 8.6%. For some people, maximizing therapeutic lifestyle changes and using standard dosages of statins would suffice to achieve these goals. However, many persons will be unable to reach newer optional targets using 1 of the therapeutic regimens tested in the long-term clinical trials of statins.
2-6,9-11,14 High doses of potent statins (atorvastatin 80 mg or simvastatin 80 mg daily) that reduce LDL-C by more than 40% have been tested for up to 2 years in very high-risk populations. 7, 8, 12, 13, 15 Since the publication of the 2004 NCEP update, the safety of atorvastain 80 mg daily for up to 5 years was demonstrated in 5,000 persons under 76 years of age with stable CHD. 15 Evidence of long-term safety of the potent rosuvastatin is not yet available. Widespread use of high-dose statin therapy could lead to higher rates of adverse effects such as rhabdomyolysis if individuals who were excluded from most clinical trials (i.e., the elderly, individuals with renal or hepatic impairment or who use medications that interact with statins) are exposed to high-dose statins in real-world settings. 28 The authors of the 2004 NCEP report acknowledge that optional LDL-C goals may be out of reach for some patients given the limitations of currently available lipid-lowering agents, and their recommendations allow for individualized clinical judgment. 18 For many patients, the decision will be
whether to use well-tested medications at dosages that have proven clinical benefits but cannot achieve the optional NCEP LDL-C goals, or to use drugs in combination or at higher doses. High-dose statin therapy or combination drug therapy (such as combining a statin with a bile acid sequestrant, niacin, a fibric acid derivative, and/or ezetimibe) may enable some additional individuals to achieve lower LDL-C goals but these options are likely to come at greater expense and have less long-term safety and efficacy data to support their use. Future studies should assess the long-term risks and benefits of combination cholesterol-lowering medical therapy and to determine whether combination or single drug treatment is preferred for high-and intermediate-risk individuals. may enable more individuals to benefit from cholesterol-lowering therapy. Furthermore, much of the cost of cholesterol treatment for high-risk individuals may be offset by reductions in the direct and indirect cost of CHD; for some high-risk subgroups, drug therapy to lower cholesterol may even be costsaving. 31, 32 The ATP III recommendation to consider medication use for adults with fewer than 2 concomitant risk factors and an LDL-C level between 160 and 189 mg/dL (6.6% of adults) warrants comment. These individuals have lower short-term CHD risk than the participants in primary prevention trials who were middle-aged and had other risk factors such as hypertension, current smoking, or low HDL-C. 3, 6, 7 The cost-effectiveness of using cholesterol-lowering drug treatment depends on treatment costs, the population's CHD and stroke risk, and the age of the population (for persons with similar CHD risk, cholesterol lowering is more cost effective for younger adults). 21 For persons in this optional ATP III treatment group with LDL-C levels between 160 and 189 mg/dL, the 10-year CHD risk is low (approximately 2%). If statin therapy is assumed to reduce the CHD event rate by 30%, 1,670 personyears of treatment would be required to prevent 1 CHD event.
At $450 per person per year, the medication costs to prevent this event would be at least $750,000 and subsequent office visits and monitoring would raise costs further. While a formal cost-effectiveness analysis is beyond the scope of our investigation, we believe that treating people in this low-risk group with cholesterol-lowering medication is unlikely to be cost effective at current statin prices. Our study has several limitations. The number of individuals studied was modest. While our findings are generally in accord with analyses performed with the larger NHANES sample from 1988 to 1994, 33 we could not accurately estimate the size of some population subgroups. Results from this survey are weighted to account for the chance of selection, nonparticipation, and excluding nonfasting persons; however, our findings might be less generalizable if excluded persons or nonparticipants had fasting LDL-C levels substantially different from study participants. Our population estimates of the number of adults with LDL-C levels exceeding goals may be underestimates for several reasons. We did not account for the proportion of the population represented by the 5.9% of the sample meeting exclusion criteria. In addition, we did not estimate the number of adults 80 years and older who may be eligible for cholesterol-lowering therapy. 9 We likely underestimated the proportion of adults with LDL-C levels above guideline goals because we may have classified some of the subgroup using cholesterol-lowering medication as lower risk when their pretreatment lipoprotein values would have placed them in a higher risk group. We did not have a precise measure of atherosclerotic cerebrovascular disease. We may have misclassified some patients with carotid atherosclerosis as lower risk, and may have misclassified some subjects with nonatheroembolic strokes as high risk. Lastly, we may have misclassified the risk group for some individuals because the medical and family history data were self-reported. In summary, many U.S. adults, especially those at increased cardiovascular risk, have uncontrolled LDL-cholesterol by 2001 ATP III guidelines. Optional LDL-C targets from 2004 greatly increased the number of individuals for whom drug therapy may be needed to reach therapeutic targets. A substantial number of people are unlikely to achieve optional NCEP LDL-C goals with standard-dose statins. Current costs of these drugs may place them out of reach for many patients likely to benefit from them. Research is needed to define longterm risks, benefits, and cost-effectiveness of combination cholesterol-lowering drug therapy compared with high-dose statin therapy alone.
